Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure i...
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
- Associated Therapies
- -
Dose Finding Study of CHF 4226 for Treating Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 278
- Registration Number
- NCT00605891
- Locations
- 🇨🇿
Ordinace pro nemoci dychaciho ustroji, Beroun, Czech Republic
🇺🇸University Clinical Research - DeLand, LLC, DeLand, Florida, United States
🇵🇱NZOZ Non-nocere, Gdansk, Poland
How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00595361
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Arthur F Gelb MD
- Target Recruit Count
- 39
- Registration Number
- NCT00568347
- Locations
- 🇺🇸
Arthur F Gelb MD, Lakewood, California, United States
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
- Conditions
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7376
- Registration Number
- NCT00563381
- Locations
- 🇦🇹
205.389.1020 Boehringer Ingelheim Investigational Site, Feldbach, Austria
🇦🇹205.389.1002 Boehringer Ingelheim Investigational Site, Wien, Austria
🇨🇿205.389.1204 Boehringer Ingelheim Investigational Site, Brno-Kralovo Pole, Czech Republic
Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD
- Conditions
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 103
- Registration Number
- NCT00535366
- Locations
- 🇧🇪
1249.1.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇧🇪1249.1.32001 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇳🇱1249.1.31003 Boehringer Ingelheim Investigational Site, Harderwijk, Netherlands
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol
- Conditions
- Interventions
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 27
- Registration Number
- NCT00531050
- Locations
- 🇧🇪
Novartis Investigative site, Antwerp, Belgium
A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.
- Conditions
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2010-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT00468975
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00422604
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Dose Ranging Study for Indacaterol in Japanese Asthma Patients
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT00403754
- Locations
- 🇯🇵
Novartis, Tokyo, Japan
🇯🇵Novartis Investigator Site, Yokohama, Japan
🇯🇵Novartis Investigative Site, Tokyo, Japan
GSK159802 In Healthy Male Subjects And Asthmatics
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 43
- Registration Number
- NCT00364273
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.